The Competition Commission of India has ordered an investigation into charges that Roche tried to block a more affordable biosimilar version of its Herceptin breast cancer drug.
Although the agency did not issue a final opinion, its order suggested that Roche moved to eliminate competition after reviewing communications the drug maker sent to the Drugs Controller General of India and the National Pharmaceutical Pricing Authority, as well as doctors and hospitals.
“The practices adopted by Roche Group … appear to be aimed at adversely affecting the penetration of biosimilars in the market,” the competition watchdog agency wrote in its April 21 interim order.
About the Author Reprints
